Malaria Vaccine Ready for Human Trials One of SBRI's breakthrough research discoveries is the development of a promising malaria vaccine candidate by Principal Investigator Stefan Kappe, Ph.D. His vaccine proved 100 percent
effective 100 percent of the time against the lethal malaria parasite infecting
mice.
Kappe and his collaborators have published new findings in the Proceedings of the National Academy of Sciences (PNAS), which prove that Kappe can replicate success in the human form of the parasite.
The Seattle Times and KPLU report on these findings and the highly-anticipated transition from "mice to men" as SBRI prepares for human clinical trials of the malaria vaccine candidate.
For more information, read
the related press release.
|
BioQuest Academy
Nearly 50 high school
juniors from across Washington State are gladly trading two weeks of summer sloth
for stimulating science at SBRI's BioQuest Academy.
Why? Because these dedicated teens want to jumpstart their futures as scientists and global health leaders.
What goes on at BioQuest Academy? See for yourself!
Stop in on one of the two remaining Academy sessions held July 27-Aug 7, and August
10-21, 9 a.m.-3 p.m. |
Research Congress Success
In June 2009, an invitation-only convening of nearly 100 leading scientists, funding organization leaders and policy leaders from around the world attended the inaugural Global Health Research Congress in Seattle. The Congress, which was chaired by SBRI President Ken Stuart, Ph.D., focused on tuberculosis (TB) and consisted of expert panels that discussed new insights into infectious disease research. Those insights will be used to drive shared research directions forward. Efforts are underway to plan for the next Congress in 2010. 
Check out event photos on SBRI's Facebook page.
|
